目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET SIZE ESTIMATION
2.2.2 INSIGHTS FROM PRIMARY SOURCES
2.2.3 TOP-DOWN APPROACH
2.3 GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 MRNA SYNTHESIS & MANUFACTURING MARKET OVERVIEW
4.2 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT AND COUNTRY, 2023
4.3 MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET: GLOBAL GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rise in clinical trials for mRNA vaccines
5.2.1.2 Continuous improvements in design, delivery systems, and manufacturing processes
5.2.1.3 Increased outsourcing of mRNA synthesis and production
5.2.1.4 Advantages of mRNA-based technology over recombinant expression
5.2.2 RESTRAINTS
5.2.2.1 High production cost
5.2.2.2 Stringent regulations
5.2.3 OPPORTUNITIES
5.2.3.1 Ongoing innovations in nanoparticles and cell-specific delivery technologies
5.2.3.2 Expanding applications of mRNA technology
5.2.3.3 Increased government funding and private investments
5.2.4 CHALLENGES
5.2.4.1 Stability, storage, and manufacturing scalability issues
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 REGULATORY LANDSCAPE
5.4.1 REGULATORY SCENARIO
5.4.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.5 VALUE CHAIN ANALYSIS
5.6 TECHNOLOGY ANALYSIS
5.6.1 KEY TECHNOLOGIES
5.6.1.1 In vitro transcription
5.6.1.2 Poly(A) tail synthesis
5.6.1.3 RNA stabilization technologies
5.6.2 COMPLEMENTARY TECHNOLOGIES
5.6.2.1 Next-generation sequencing
5.6.2.2 Gene cloning and vector construction
5.6.2.3 DNA amplification
5.6.3 ADJACENT TECHNOLOGIES
5.6.3.1 Spectrophotometry
5.6.3.2 Electrophoresis
5.6.3.3 High-performance liquid chromatography
5.7 PRICING ANALYSIS
5.7.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY INSTRUMENT
5.7.2 AVERAGE SELLING PRICE TREND FOR CONSUMABLES
5.7.3 AVERAGE SELLING PRICE, BY REGION
5.8 PATENT ANALYSIS
5.9 SUPPLY CHAIN ANALYSIS
5.10 ECOSYSTEM ANALYSIS
5.11 KEY CONFERENCES AND EVENTS, 2024-2025
5.12 PORTER'S FIVE FORCES ANALYSIS
5.12.1 INTENSITY OF COMPETITIVE RIVALRY
5.12.2 BARGAINING POWER OF SUPPLIERS
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 THREAT OF SUBSTITUTES
5.12.5 THREAT OF NEW ENTRANTS
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.13.2 KEY BUYING CRITERIA, BY END USER (PRODUCT)
5.14 INVESTMENT AND FUNDING SCENARIO
5.15 IMPACT OF AI ON MRNA SYNTHESIS & MANUFACTURING MARKET

6 MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 CONSUMABLES
6.2.1 TRANSCRIPTION CONSUMABLES
6.2.1.1 mRNA synthesis kits
6.2.1.1.1 Increasing demand for rapid and efficient mRNA vaccine development to augment growth
6.2.1.2 mRNA profiling kits
6.2.1.2.1 Growing need for precision medicine and personalized therapies to propel market
6.2.1.3 RNA polymerases
6.2.1.3.1 Growing demand for high-quality and scalable mRNA production to boost market
6.2.1.4 Plasmid DNA/DNA templates
6.2.1.4.1 Rapid growth of mRNA-based therapeutics and vaccines to expedite growth
6.2.1.5 Nucleotides
6.2.1.5.1 Need to support diverse research & development initiatives to promote growth
6.2.1.6 Vectors
6.2.1.6.1 Need for reliable and high-capacity vectors to propel market
6.2.1.7 Other transcription consumables
6.2.2 PURIFICATION CONSUMABLES
6.2.2.1 Purification kits & reagents
6.2.2.1.1 Rising focus on quality assurance to encourage growth
6.2.2.2 Chromatography filters & membranes
6.2.2.2.1 Growing emphasis on process optimization and cost-efficiency in large-scale production to drive market
6.2.2.3 Other purification consumables
6.2.3 ANALYSIS & CHARACTERIZATION CONSUMABLES
6.2.3.1 Analysis kits & reagents
6.2.3.1.1 Emerging applications of mRNA beyond vaccines to support growth
6.2.3.2 Other analysis & characterization consumables
6.3 INSTRUMENTS
6.3.1 NEED TO REDUCE PRODUCTION COST AND HIGHER SCALABILITY TO PROMOTE GROWTH

7 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 CELL & GENE THERAPIES
7.2.1 RISING ADOPTION OF MRNA TECHNOLOGY TO TREAT GENETIC DISORDERS AND CANCER TO FUEL MARKET
7.3 VACCINES
7.3.1 INCREASING DEVELOPMENT AND DEPLOYMENT OF MRNA VACCINES TO ACCELERATE GROWTH
7.4 OTHER APPLICATIONS

8 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER
8.1 INTRODUCTION
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.2.1 NEED TO RESPOND TO EMERGING INFECTIOUS DISEASES TO DRIVE MARKET
8.3 ACADEMIC & RESEARCH INSTITUTIONS
8.3.1 INCREASING INVESTMENTS IN RESEARCH TO EXPEDITE GROWTH
8.4 CROS & CDMOS
8.4.1 RISING DEMAND FOR OUTSOURCED SERVICES TO AID GROWTH

9 MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE
9.1 INTRODUCTION
9.2 MRNA SYNTHESIS & MODIFICATION SERVICES
9.2.1 GROWING NEED FOR CUSTOMIZED MRNA SEQUENCES AND MODIFICATIONS TO FUEL MARKET
9.3 MRNA PURIFICATION SERVICES
9.3.1 NEED FOR PERSONALIZED MRNA VACCINES TO BOOST MARKET
9.4 MRNA ANALYSIS & CHARACTERIZATION SERVICES
9.4.1 INCREASING REGULATORY SCRUTINY TO EXPEDITE GROWTH
9.5 MANUFACTURING & SCALE-UP SERVICES
9.5.1 GROWING TRANSITION FROM SMALL-SCALE RESEARCH & DEVELOPMENT TO LARGE-SCALE COMMERCIAL PRODUCTION TO DRIVE MARKET

10 MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER
10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 RAPID DEVELOPMENT AND COMMERCIALIZATION OF MRNA-BASED PRODUCTS TO ENCOURAGE GROWTH
10.3 ACADEMIC & RESEARCH INSTITUTIONS
10.3.1 INCREASING EMPHASIS ON TRANSLATING MRNA-BASED DISCOVERIES INTO PRACTICAL APPLICATIONS TO AID GROWTH
10.4 SMALL-SCALE CROS & CDMOS
10.4.1 NEED FOR SPECIALIZED AND FLEXIBLE PRODUCTION IN BIOTECH COMPANIES AND EARLY-STAGE MRNA PROJECTS TO BOOST MARKET

11 MRNA SYNTHESIS & MANUFACTURING MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2.1 Increasing demand for mRNA-based vaccines and therapeutics to accelerate growth
11.2.3 CANADA
11.2.3.1 Increasing collaborations between academic institutions and market players to spur growth
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2.1 Growing establishment of manufacturing sites to boost market
11.3.3 UK
11.3.3.1 Presence of state-of-the-art facilities to support growth
11.3.4 FRANCE
11.3.4.1 Favorable government support for biopharmaceutical production to drive market
11.3.5 SWITZERLAND
11.3.5.1 Robust biotech sector and production facilities to promote growth
11.3.6 ITALY
11.3.6.1 Increasing collaborations among biotech firms and manufacturing facilities to aid growth
11.3.7 SPAIN
11.3.7.1 Growing investments in biotechnology to fuel market
11.3.8 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 CHINA
11.4.2.1 Rapid expansion of domestic biotech sector to contribute to growth
11.4.3 JAPAN
11.4.3.1 Growing strategic investments in biotechnology infrastructure to boost market
11.4.4 INDIA
11.4.4.1 Booming biotech sector and international collaborations to augment growth
11.4.5 SOUTH KOREA
11.4.5.1 Increased government funding in research and vaccine development to bolster growth
11.4.6 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 Increased funding for strengthening infrastructure to sustain growth
11.5.3 REST OF LATIN AMERICA
11.6 MIDDLE EAST
11.6.1 GROWING INVESTMENTS FROM PRIVATE SECTOR AND ACADEMIC RESEARCH INITIATIVES TO DRIVE MARKET
11.6.2 MACROECONOMIC OUTLOOK IN MIDDLE EAST
11.7 AFRICA
11.7.1 GROWING INITIATIVES TO ENHANCE LOCAL PRODUCTION CAPABILITIES TO PROPEL MARKET
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2021-AUGUST 2024
12.3 REVENUE ANALYSIS, 2019-2023
12.4 MARKET SHARE ANALYSIS, 2023
12.4.1 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET
12.4.2 MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET
12.5 COMPANY VALUATION AND FINANCIAL METRICS
12.6 BRAND/SERVICE COMPARISON
12.6.1 ALDEVRON LLC (DANAHER CORPORATION) (US)
12.6.2 THERMO FISHER SCIENTIFIC INC. (US)
12.6.3 TRILINK BIOTECHNOLOGIES (US)
12.6.4 LONZA (SWITZERLAND)
12.6.5 MERCK KGAA (GERMANY)
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.7.1 STARS
12.7.2 EMERGING LEADERS
12.7.3 PERVASIVE PLAYERS
12.7.4 PARTICIPANTS
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.7.5.1 Company footprint
12.7.5.2 Region footprint
12.7.5.3 Product footprint
12.7.5.4 Service footprint
12.7.5.5 Application footprint
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.8.1 PROGRESSIVE COMPANIES
12.8.2 RESPONSIVE COMPANIES
12.8.3 DYNAMIC COMPANIES
12.8.4 STARTING BLOCKS
12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.8.5.1 Detailed list of key startups/SMEs
12.8.5.2 Competitive benchmarking of key startups/SMES
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT/SERVICE LAUNCHES
12.9.2 DEALS
12.9.3 EXPANSIONS

13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 THERMO FISHER SCIENTIFIC INC.
13.1.1.1 Business overview
13.1.1.2 Products/Services offered
13.1.1.3 Recent developments
13.1.1.3.1 Product/Service launches
13.1.1.3.2 Deals
13.1.1.3.3 Expansions
13.1.1.4 MnM view
13.1.1.4.1 Key strengths
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses and competitive threats
13.1.2 DANAHER CORPORATION
13.1.2.1 Business overview
13.1.2.2 Products/Services offered
13.1.2.3 Recent developments
13.1.2.3.1 Product/Service launches
13.1.2.3.2 Deals
13.1.2.3.3 Expansions
13.1.2.4 MnM view
13.1.2.4.1 Key strengths
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses and competitive threats
13.1.3 MERCK KGAA
13.1.3.1 Business overview
13.1.3.2 Products/Services offered
13.1.3.3 Recent developments
13.1.3.3.1 Deals
13.1.3.3.2 Expansions
13.1.3.4 MnM view
13.1.3.4.1 Key strengths
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses and competitive threats
13.1.4 LONZA
13.1.4.1 Business overview
13.1.4.2 Products/Services offered
13.1.4.3 Recent developments
13.1.4.3.1 Deals
13.1.4.3.2 Expansions
13.1.4.4 MnM view
13.1.4.4.1 Key strengths
13.1.4.4.2 Strategic choices
13.1.4.4.3 Weaknesses and competitive threats
13.1.5 MARVAI LIFESCIENCES
13.1.5.1 Business overview
13.1.5.2 Products/Services offered
13.1.5.3 Recent developments
13.1.5.3.1 Product/Service launches
13.1.5.3.2 Deals
13.1.5.3.3 Expansions
13.1.5.4 MnM view
13.1.5.4.1 Key strengths
13.1.5.4.2 Strategic choices
13.1.5.4.3 Weaknesses and competitive threats
13.1.6 NEW ENGLAND BIOLABS
13.1.6.1 Business overview
13.1.6.2 Products/Services offered
13.1.6.3 Recent developments
13.1.6.3.1 Product/Service launches
13.1.7 PROMEGA CORPORATION
13.1.7.1 Business overview
13.1.7.2 Products/Services offered
13.1.7.3 Recent developments
13.1.7.3.1 Expansions
13.1.7.3.2 Other developments
13.1.8 GENSCRIPT
13.1.8.1 Business overview
13.1.8.2 Products/Services offered
13.1.8.3 Recent developments
13.1.8.3.1 Product/Service launches
13.1.8.3.2 Deals
13.1.8.3.3 Expansions
13.1.8.4 MnM view
13.1.8.4.1 Key strengths
13.1.8.4.2 Strategic choices
13.1.8.4.3 Weaknesses and competitive threats
13.1.9 WUXI BIOLOGICS
13.1.9.1 Business overview
13.1.9.2 Products/Services offered
13.1.9.3 Recent developments
13.1.9.3.1 Expansions
13.1.10 TAKARA BIO INC.
13.1.10.1 Business overview
13.1.10.2 Products/Services offered
13.1.10.3 Recent developments
13.1.10.3.1 Product/Service launches
13.1.10.3.2 Deals
13.1.11 SARTORIUS AG
13.1.11.1 Business overview
13.1.11.2 Products/Services offered
13.1.11.3 Recent developments
13.1.11.3.1 Deals
13.1.12 GENEWIZ
13.1.12.1 Business overview
13.1.12.2 Products/Services offered
13.1.13 TELESIS BIO INC.
13.1.13.1 Business overview
13.1.13.2 Products/Services offered
13.1.13.3 Recent developments
13.1.13.3.1 Product/Service launches
13.1.13.3.2 Deals
13.1.14 ST PHARM
13.1.14.1 Business overview
13.1.14.2 Products/Services offered
13.1.14.3 Recent developments
13.1.14.3.1 Deals
13.1.15 AGC BIOLOGICS
13.1.15.1 Business overview
13.1.15.2 Products/Services offered
13.1.15.3 Recent developments
13.1.15.3.1 Deals
13.1.15.3.2 Expansions
13.1.16 DR. REDDY'S LABORATORIES LTD.
13.1.16.1 Business overview
13.1.16.2 Products/Services offered
13.1.16.3 Recent developments
13.1.16.3.1 Expansions
13.2 OTHER PLAYERS
13.2.1 ETHERNA
13.2.2 BOC SCIENCES
13.2.3 BIOMAY AG
13.2.4 CURIA GLOBAL, INC.
13.2.5 JENA BIOSCIENCE GMBH
13.2.6 ENZYNOMICS CO., LTD.
13.2.7 KANEKA EUROGENTEC S.A.
13.2.8 VERNAL BIOSCIENCES
13.2.9 CELLSCRIPT

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS